Anti-inflammatory mode of isoflavone glycoside sophoricoside by inhibition of interleukin-6 and cyclooxygenase-2 in inflammatory response.
Soy, high dietary intake for the oriental population, is a main source of isoflavonoids. Sophoricoside (SOP) an isoflavone glycoside was isolated from immature fruits of Sophora japonica (Leguminosae family) and its inhibitory effect on chemical mediators involved in inflammatory response was investigated in this study. SOP inhibited the interleukin (IL)-6 bioactivity with an IC50 value of 6.1 microM whereas it had no effects on IL-1beta and TNF-alpha bioactivities. SOP was identified as a selective inhibitor of cyclooxygenase (COX)-2 activity with an IC50 value of 4.4 microM, but did not show inhibitory effect on the synthesis of COX-2. However, SOP had no effect on the production of reactive oxygen species including superoxide anions and nitric oxide. These results revealed that in vitro anti-inflammatory action of SOP is significantly different from that of genistein known as a phytoestrogen of soy products. This experimental study has documented an importance of dietary soy isoflavonoids as multifunctional agents beneficial to human health, and will help to clarify protective mechanisms of SOP against inflammatory conditions.
Kim
Byung Hak
BH
College of Pharmacy and Research Center for Bioresource and Health, Chungbuk National University, Cheongju 361-763, Korea.
Chung
Eun Yong
EY
Ryu
Jae-Chun
JC
Jung
Sang-Hun
SH
Min
Kyung Rak
KR
Kim
Youngsoo
Y
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D001578:Benzopyrans / Q000494:pharmacology*; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D006801:Humans; D066298:In Vitro Techniques; D007249:Inflammation / Q000139:chemically induced / Q000188:drug therapy* / Q000517:prevention & control*; D007375:Interleukin-1 / Q000378:metabolism; D007527:Isoenzymes / Q000009:adverse effects / Q000037:antagonists & inhibitors*; D007723:Korea; D008565:Membrane Proteins; D051379:Mice; D009569:Nitric Oxide / Q000037:antagonists & inhibitors* / Q000378:metabolism; D018514:Plant Structures / Q000737:chemistry; D011451:Prostaglandin-Endoperoxide Synthases / Q000009:adverse effects; D017382:Reactive Oxygen Species / Q000037:antagonists & inhibitors* / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D000093242:Interleukin-6 Inhibitors
D000893:Anti-Inflammatory Agents; D001578:Benzopyrans; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D007375:Interleukin-1; D007527:Isoenzymes; D008565:Membrane Proteins; D009569:Nitric Oxide; D011451:Prostaglandin-Endoperoxide Synthases; D017382:Reactive Oxygen Species; D014409:Tumor Necrosis Factor-alpha; D000093242:Interleukin-6 Inhibitors; C120642:sophoricoside; C496511:PTGS1 protein, human; C496540:PTGS2 protein, human; C496512:Ptgs1 protein, mouse